Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 13

Opinion

Video

July 24, 2024

Multiple Sclerosis: Looking Toward the Future

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Heidi Crayton, MD

Heidi Crayton, MD, and Maria Lopes, MD, discuss future research in multiple sclerosis that they find exciting and promising.

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

Now Viewing

EP: 13.Multiple Sclerosis: Looking Toward the Future

Video content above is prompted by the following question:

Are there any areas of future research in multiple sclerosis (MS) that you are excited for?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

Health care cure concept with a hand in blue medical gloves holding Coronavirus, Covid 19 virus, vaccine vial | Image credit: Leigh Prather - stock.adobe.com

July 8th 2025

Multinational Study Highlights COVID-19 Vaccine Safety in MS

Skylar Jeremias

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.

November 30th 2021

Millennials With Multiple Sclerosis: Are They Different or Has Medicine Evolved?

On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com

April 9th 2025

Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

Rose McNulty

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

December 1st 2019

Podcast: This Week in Managed Care—Challenges of Rural Healthcare Delivery and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg

March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com

January 9th 2025

Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

AJMC Contributor

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).